| abstract |
3-arylindole or 3-arylindazole derivatives having the general formula I, [wherein Ar is an optionally substituted phenyl or heteroaromatic group; R-R are hydrogen, halogen, alkyl, alkoxy, hydroxy, alkylthio, alkylsulfonyl, alkyl- or dialkylamino, cyan, trifluoromethyl, or trifluoromethylthio; X represents N; CR, where R is H, halogen, trifluoromethyl or alkyl; or CH; Y represents N, CH, or C; R is H, alkyl, alkenyl, cycloalkyl, or cycloalkylalkyl; or R 1 represents a substituent of formula (Ia) or (Ib), where n is 2-6; W is O or S; U is N or CH; Z is - (CH) -, -CH = CH-, phenylene, -COCH-, or -CSCH-; V is O, S, CH or NR, where R is H, alkyl, alkenyl, cycloalkyl or cycloalkylalkyl; U is O, S, CH or NR, and V is NRR, ORSR or CRRR, where each RR is as defined for R], inhibit the excitation of spontaneously active dopamine neurons in the ventral region of the cerebral cortex, as a result of which these compounds can be used for the treatment of psychoses in humans |